Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study

Masaaki Hotta, Ayako Iwama, Tokiko Hoshiyama, Yukie Tsubokura, Hideaki Yoshimura, Yumiko Kono, Shinya Fujita, Atsushi Satake, Tomoki Ito

Blood (2023) 142 (Supplement 1): 3107.

https://doi.org/10.1182/blood-2023-173434

Published: 2023

Journal Articles

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Masaaki Hotta, MD, Satake Atsushi, MD PhD, Yukie Tsubokura, MD, Yoshiko Azuma, MD, Hideaki Yoshimura, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Tomoki Ito, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2019) 134 (Supplement_1): 5672.

https://doi.org/10.1182/blood-2019-129959

Published: 2019

Journal Articles

Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?

Aya Nakaya, MD PhD, Shinya Fujita, MD PhD, Atsushi Satake, MD PhD, Takahisa Nakanishi, MD PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Ryo Saito, MD, Akiko Konishi, MD, Masaaki Hotta, MD, Hideaki Yoshimura, MD, Kazuyoshi Ishii, MD MPH, PhD, Tomoki Ito, MD PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 5402.

https://doi.org/10.1182/blood-2018-99-117823

Published: 2018

Journal Articles

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

Yoshiko Azuma, MD, Tomoki Ito, MD PhD, Muneo Inaba, PhD, Kai Imai, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 1938.

https://doi.org/10.1182/blood-2018-99-113282

Published: 2018

Journal Articles

A Critical Role of Host-Derived Semaphorin-4A for Regulating T Cell Immune Responses in Acute Graft Versus Host Disease

Hideaki Yoshimura, MD, Yukie Tsubokura, MD, Masaaki Hotta, MD, Atsushi Satake, MD PhD, Tomoki Ito, MD PhD, Atsushi Kumanogoh, MD PhD, Shosaku Nomura, MD PhD

Blood (2018) 132 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2018-99-113853

Published: 2018

Journal Articles

Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis

Atsushi Satake, MD PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Tomoki Ito, MD PhD, Kazuyoshi Ishii, Shosaku Nomura, MD PhD

Blood (2017) 130 (Supplement 1): 4092.

https://doi.org/10.1182/blood.V130.Suppl_1.4092.4092

Published: 2017

Journal Articles

Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells

Tomoki Ito, MD PhD, Kayoko Kibata, MD, Muneo Inaba, PhD, Yoshiko Azuma, MD, Yukie Tsubokura, MD, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MDMPH,PhD, Shosaku Nomura, MD PhD

Blood (2017) 130 (Supplement 1): 1007.

https://doi.org/10.1182/blood.V130.Suppl_1.1007.1007

Published: 2017

Journal Articles

Immunomodulatory Drugs (IMiDs), Lenalidomide and Pomalidomide, Suppress Th1-Inducing Capacity of Dendritic Cells but Enhance Th2-Mediated Allergic Response

Tomoki Ito, M. D. and Ph. D., Phan Thi Xuan Vien, Muneo Inaba, Ph. D, Hideaki Yoshimura, MD, Masaaki Hotta, MD, Takahisa Nakanishi, MD PhD, Shinya Fujita, MD PhD, Aya Nakaya, MD PhD, Atsushi Satake, MD PhD, Kazuyoshi Ishii, MD MPH, PhD, Shosaku Nomura, MD PhD

Blood (2016) 128 (22): 2520.

https://doi.org/10.1182/blood.V128.22.2520.2520

Published: 2016

Journal Articles

GM-CSF Therapy Expands Regulatory T Cells and Protects Against Chronic Graft Versus Host Disease

Hideaki Yoshimura, MD, Masaaki Hotta, MD, Atsushi Satake, MD PhD, Shosaku Nomura, MD PhD

Blood (2016) 128 (22): 2151.

https://doi.org/10.1182/blood.V128.22.2151.2151

Published: 2016

NARROW

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Diffuse Large B-Cell Lymphoma in the Real-World Setting: A Single Institute Retrospective Study

Plasma Biomarker Predicts Lethal Acute Graft Versus Host Disease and Non-Relapse Mortality in Japanese Patients

Does Neutrophil to Lymphocyte Ratio (NLR) Predict the Prognosis of Diffuse Large B-Cell Lymphoma?

Myeloma Cells Have the Ability to Suppress Th1-Inducing Capacity but Enhance Th2-Mediated Response of Dendritic Cells By Producing Factors Other Than Soluble SLAMF7

A Critical Role of Host-Derived Semaphorin-4A for Regulating T Cell Immune Responses in Acute Graft Versus Host Disease

Clinical Impact of Mogamulizumab Against Aggressive ATL: A Single-Center Retrospective Analysis

Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells

Immunomodulatory Drugs (IMiDs), Lenalidomide and Pomalidomide, Suppress Th1-Inducing Capacity of Dendritic Cells but Enhance Th2-Mediated Allergic Response

GM-CSF Therapy Expands Regulatory T Cells and Protects Against Chronic Graft Versus Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only